Duo Oncology

Executive Summary

Duo Oncology is a preclinical-stage biotechnology company pioneering a novel nanomedicine platform that mimics DNA self-assembly to create ultra-small, tumor-penetrating particles. Each nanoparticle carries a duo of anti-cancer therapies and is designed to extravasate deep into tumor tissue, where the unique tumor microenvironment cleaves environmentally sensitive bonds to release the therapies precisely at the site of action. This approach aims to overcome the limitations of conventional cancer treatments for difficult-to-target tumors by improving drug delivery and reducing systemic toxicity. Founded in 2020 and based in Cambridge, MA, Duo Oncology operates in the nanotechnology space with a focus on foundational therapies that could transform the treatment landscape. The company is privately held and has not publicly disclosed its funding or valuation, reflecting its early stage of development. While no specific pipeline candidates have been announced, the platform's potential applicability across multiple cancer types positions it for future clinical advancement. Key upcoming catalysts include preclinical proof-of-concept data, IND-enabling studies, and potential strategic partnerships, though timelines remain uncertain due to the company's nascent stage.

Upcoming Catalysts (preview)

• TBDPublication of preclinical in vivo efficacy data for lead duo-nanoparticle candidate70% success
• TBDCompletion of IND-enabling toxicology studies and filing of Investigational New Drug application40% success
• TBDAnnouncement of corporate partnership or licensing deal for platform technology30% success